Stockscreener 앱 받기
6.85
5.52%
-0.40
전일 마감가:
$7.25
열려 있는:
$7.1
하루 거래량:
1.02M
Relative Volume:
1.87
시가총액:
$452.60M
수익:
순이익/손실:
$-44.47M
주가수익비율:
-6.7282
EPS:
-1.0181
순현금흐름:
$-33.50M
1주 성능:
-0.29%
1개월 성능:
-24.73%
6개월 성능:
-12.18%
1년 성능:
+28.52%
1일 변동 폭
$6.41
$7.10
1주일 범위
$6.64
$7.51
52주 변동 폭
$5.25
$9.32
Eupraxia Pharmaceuticals Inc Stock (EPRX) Company Profile
Compare EPRX vs VRTX, REGN, MRNA, ARGX, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
EPRX
Eupraxia Pharmaceuticals Inc
|
6.85 | 452.60M | 0 | -44.47M | -33.50M | -1.0181 |
VRTX
Vertex Pharmaceuticals Inc
|
559.57 | 141.83B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
927.84 | 95.53B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
221.85 | 88.57B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
892.43 | 56.12B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
370.17 | 41.87B | 5.76B | 514.49M | 1.10B | 4.4813 |
Eupraxia Pharmaceuticals Inc Stock (EPRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-09-24 | 개시 | Wedbush | Outperform |
| 2026-06-26 | 개시 | Oppenheimer | Outperform |
| 2026-05-21 | 개시 | Stifel | Buy |
| 2026-03-23 | 개시 | William Blair | Outperform |
| 2025-07-24 | 개시 | Cantor Fitzgerald | Overweight |
| 2025-06-26 | 개시 | H.C. Wainwright | Buy |
| 2025-06-16 | 개시 | Canaccord Genuity | Speculative Buy |
| 2025-02-21 | 개시 | Craig Hallum | Buy |
| 2024-11-14 | 개시 | Rodman & Renshaw | Buy |
모두보기
Eupraxia Pharmaceuticals Inc 주식(EPRX)의 최신 뉴스
When (EPRX.WT.A) Moves Investors should Listen - Stock Traders Daily
Eupraxia Pharmaceuticals: Promising Science, But Competition And Valuation Limit Upside - Seeking Alpha
Why Eupraxia Pharmaceuticals, Inc. Is on Investors’ Radar: Key Catalysts to Watch on TSX:EPRX - kalkine.ca
(EPRX.WT.A) Trading Advice (EPRX.WT.A:CA) - Stock Traders Daily
Eupraxia Pharmaceuticals to Present at Upcoming American College of Gastroenterology (ACG) and United European Gastroenterology (UEG) Medical Conferences - GlobeNewswire Inc.
Eupraxia Pharmaceuticals Reports 52-Week Data from the Highest Dose Cohort of EP-104GI in its Ongoing Phase 1b/2a RESOLVE Trial for the Treatment of Eosinophilic Esophagitis - GlobeNewswire Inc.
Fifty-two weeks after one dose, 9 of 14 patients with an esophageal disease remained in remission. - Stock Titan
Eupraxia Pharmaceuticals (TSX:EPRX) Stock Slips 5.13%: RESOLVE Trial Execution, Diffusphere Formulation Pacing, and Pre-Commercial Valuation Scrutinized - kalkine.ca
Wall Street Analysts See a 145.35% Upside in Eupraxia Pharmaceuticals Inc. (EPRX): Can the Stock Really Move This High? - Eastern Progress
Eupraxia Pharmaceuticals Inc. (TSX:EPRX) Rises 5.51% as Clinical Momentum and Nasdaq Upgrade Support Investor Sentiment - kalkine.ca
Eupraxia Pharma (EPRX): When Painful Swallowing Nearly Disappeared, Investors Took Notice - Yahoo Finance
EPRX: Innovative annual therapy for EoE shows rapid, durable efficacy and strong commercial prospects - TradingView
Eupraxia Pharmaceuticals Inc. Common Stock (EPRX) Stock Price Today: $8.25 - Gotrade
Why Eupraxia Pharmaceuticals Inc stock is skyrocketing today - Wealth Awesome
Eupraxia Pharmaceuticals Completes Transfer to the Nasdaq Global Select Market and Announces Participation in Upcoming Investor Conferences - Investing News Network
Eupraxia Pharmaceuticals Moves Up to Nasdaq Global Select Market and Ramps Investor Outreach - TipRanks
Why Did Eupraxia Pharmaceuticals (TSX:EPRX) Surge 12.36% on 4 September 2026? - kalkine.ca
Pharma Eupraxia (Nasdaq: EPRX) moves to Nasdaq's top tier - Stock Titan
No shareholder action is needed as Eupraxia shares move to Nasdaq’s highest tier. - Stock Titan
Eupraxia Pharmaceuticals Completes Transfer to the Nasdaq - GlobeNewswire
Eupraxia Pharmaceuticals Completes Transfer to the Nasdaq Global Select Market and Announces Participation in Upcoming Investor Conferences - finance.yahoo.com
Why Eupraxia Pharmaceuticals Inc stock surged yesterday - Wealth Awesome
EPRX Stock Jumps As Traders Eye Volatile Breakout - timothysykes.com
EPRX Jumps As Traders Focus On Cash Runway And Momentum - StocksToTrade
Eupraxia Pharmaceuticals Inc. (EPRX) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
Why Eupraxia Pharmaceuticals Inc stock surged yesterday - Wealth Awesome
Eupraxia Pharmaceuticals (TSX:EPRX) Gains Momentum as Clinical Progress Supports a More Constructive Investor Outlook - kalkine.ca
Eupraxia Pharmaceuticals Inc. (TSX:EPRX) Surges 9.56% Today as RESOLVE Trial Momentum and Major Q4 Catalyst Fuel Investor Optimism - kalkine.ca
Eupraxia Pharmaceuticals Stock Slides 3.34%: Can Clinical Momentum Offset Renewed Downside Pressure? - kalkine.ca
Eupraxia Pharmaceuticals Inc. (TSX:EPRX) Slides 3.34% as Clinical-Stage Risks and Biotech Volatility Pressure Sentiment - kalkine.ca
Eupraxia Pharmaceuticals Stock Falls 8.75% as Clinical-Stage Volatility Tests Investor Confidence Despite Pipeline Potential - kalkine.ca
Eupraxia Pharmaceuticals Inc. (TSX:EPRX) Faces Downside Pressure as Biotech Volatility and Clinical Execution Risks Weigh on Investor Sentiment - kalkine.ca
BetterLife Pharma Inc. Announces Pricing of US$100 Million Public Offering of Common Shares and Pre-Funded Warrants - Yahoo Finance
Could Eupraxia Pharmaceuticals (TSX:EPRX) Reach Its Next Milestone? - Kalkine Media
EUPRAXIA PHARMACEUTICALS INC. SEC Filing (Aug 25, 2026) - Stock Titan
Eupraxia Pharmaceuticals Inc. (TSX:EPRX) Gains Investor Momentum as Clinical Progress and Pipeline Advancement Strengthen Biotechnology Outlook - kalkine.ca
Could Eupraxia Pharmaceuticals (TSX:EPRX) Gain Fresh Market Attention? - Kalkine Media
Eupraxia (EPRX) Watch: Finishes 0.44% Lower at $6.73 in the Latest Reading; Technical View: $6.39 and $7.07 Define the Nearby Reference Levels under the Current SnapshotPut Call Ratio - vinanet.vn
Eupraxia Pharmaceuticals Independent Director Acquires 1.4% More Stock - simplywall.st
Eupraxia Pharmaceuticals Stock Falls 4.12% as Investors Weigh Clinical Progress Against Biotech Development and Financing Risk - kalkine.ca
Eupraxia Slides as Biotech Traders Take Risk Off the Table — What Could Trigger the Next Move? - kalkine.ca
Eupraxia Pharmaceuticals Faces Fresh Downside Pressure as Clinical Execution Risk Clouds the EoE Story - kalkine.ca
Eupraxia Pharmaceuticals Inc. Common Stock (NASDAQ: EPRX) Stock Price, News & Analysis - kalkine.ca
Eupraxia (EPRX) Quarter in Focus: EPS Does Not Reach the Reported Estimate for This Review - vinanet.vn
Eupraxia Pharmaceuticals Market Sentiment - Benzinga France
What's Going On With Eupraxia Pharmaceuticals Inc Stock Wednesday? - Wealth Awesome
Eupraxia (Nasdaq: EPRX) lines up $300M in securities offerings - Stock Titan
Eupraxia Pharmaceuticals Inc. Common Stock (NASDAQ: EPRX) Stock Price, News & Analysis - Kalkine
Eupraxia Pharmaceuticals (EPRX) Edges Higher to $6.72 as Biotech Sector Holds SteadyEqual Weight ETF - vinanet.vn
Eupraxia Pharmaceuticals announces results from RESOLVE study analysis - TipRanks
Eupraxia Pharmaceuticals Inc (EPRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
6.99%
자본화:
|
볼륨(24시간):